Presentation of Results from the MOXIe Part 2 Study, by Dr. David Lynch

Part 2 of MOXIe was an international, multi-center, double-blind, placebo-controlled Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia.

Kidney Effects in the MOXIe Trial: Presentation at ERA-EDTA 2020

Friedreich’s Ataxia (FA) is a rare, progressive, and debilitating genetic disorder with no approved treatments. Kidney function was assessed in patients with Friedreich’s ataxia in Part 2 of MOXIe, a Phase 2 international, multicenter, double-blind, randomized, placebo-controlled study of omaveloxolone in FA.

Keap1/Nrf2 Pathway Regulates GFR by Increasing the Glomerular Effective Filtration Area Without Affecting the Afferent/Efferent Arteriole Ratio: Presentation at ERA-EDTA 2020

Pharmacologic and genetic investigation of the mechanisms of GFR regulation by Nrf2 using in vivo multiphoton microscope (MPM) imaging techniques.

Publication: Omaveloxolone and TX63682 Are Hepatoprotective in the STAM Mouse Model of NASH

This preclinical study evaluated the effects of omaveloxolone and TX63682, a closely related structural analog, in the STAM mouse model of nonalcoholic steatohepatitis (NASH), a progressive form of liver disease.

Publication: TSUBAKI, a Study of Bardoxolone Methyl in Patients with Diabetic CKD

TSUBAKI was a Phase 2, randomized, multicenter, double-blind, placebo-controlled study of bardoxolone methyl in patients with type 2 diabetes and stage 3-4 chronic kidney disease. The primary efficacy endpoint was change from baseline in GFR measured by inulin clearance at week 16.